Trial Profile
Examination of tissue penetration of garenoxacin (GRNX) for peritonsillar abscess
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Mar 2018
Price :
$35
*
At a glance
- Drugs Garenoxacin (Primary)
- Indications Peritonsillar abscess
- Focus Pharmacokinetics
- 01 Mar 2018 Status changed from recruiting to completed.
- 09 Jul 2014 New trial record